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Abstract
To date, no effective method exists that predicts the response to preoperative chemoradiation (CRT) in locally advanced
rectal cancer (LARC). Nevertheless, identification of patients who have a higher likelihood of responding to preoperative CRT
could be crucial in decreasing treatment morbidity and avoiding expensive and time-consuming treatments. The aim of this
study was to identify signatures or molecular markers related to response to pre-operative CRT in LARC. We analyzed the
gene expression profiles of 26 pre-treatment biopsies of LARC (10 responders and 16 non-responders) without metastasis
using Human WG CodeLink microarray platform. Two hundred and fifty seven genes were differentially over-expressed in
the responder patient subgroup. Ingenuity Pathway Analysis revealed a significant ratio of differentially expressed genes
related to cancer, cellular growth and proliferation pathways, and c-Myc network. We demonstrated that high Gng4, c-Myc,
Pola1, and Rrm1 mRNA expression levels was a significant prognostic factor for response to treatment in LARC patients (p,
0.05). Using this gene set, we were able to establish a new model for predicting the response to CRT in rectal cancer with a
sensitivity of 60% and 100% specificity. Our results reflect the value of gene expression profiling to gain insight about the
molecular pathways involved in the response to treatment of LARC patients. These findings could be clinically relevant and
support the use of mRNA levels when aiming to identify patients who respond to CRT therapy.
Citation: Palma P, Cano C, Conde-Muiño R, Comino A, Bueno P, et al. (2014) Expression Profiling of Rectal Tumors Defines Response to Neoadjuvant Treatment
Related Genes. PLoS ONE 9(11): e112189. doi:10.1371/journal.pone.0112189
Editor: Stefan Wölfl, Heidelberg University, Germany
Received May 22, 2014; Accepted October 13, 2014; Published November 7, 2014
Copyright:  2014 Palma et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: This investigation was supported by the Fundación Investigación Biomédica Mutua Madrileña and Consejeria de Innovación y Ciencia (Proyecto de
Excelencia) de la Junta de Andalucı́a. MC, CC and AB were supported by projects CTS2200 and PI-0710-2013 of Junta de Andalucı́a, TIN2013-41990-R of Programa
Estatal I+D+i MINECO, and GREIB PYR_2010-02 and 2010_05 of University of Granada. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: mcuadros@ugr.es
. These authors contributed equally to this work.
Introduction
There has been a high local recurrence rate in locally advanced
rectal cancer (LARC). Besides improvements in surgical tech-
niques, both neoadjuvant short-course radiotherapy and long-
course chemoradiation (CRT) improve oncological results [1].
After CRT, the ability to achieve tumor reduction or even a
complete response is observed in up to 60% of the patients treated.
This treatment also correlates with a decreasing local recurrence.
Conversely patients with a poor response have a worse oncological
outcome.
To date, there is no effective method of predicting the response
to CRT and therefore such aggressive schedule is indicated for all
patients with LARC [2]. Nevertheless, identification of patients
who have a higher likelihood of responding to preoperative CRT
could be crucial in decreasing treatment morbidity and avoiding
expensive and time-consuming treatments [3]. There are un-
doubtedly many patient and tumor factors contributing to tumor
response. Genetic and molecular profiling of rectal tumours has
provided an insight into tumor biology. Gene expression profiling
has been extensively applied to study colorectal tumors, and gene
signatures for recurrence, prognosis or even response to chemo-
therapy have been described [4]. Nevertheless, to date, none of the
identified signatures or molecular markers in LARC has been
successfully validated as a diagnostic or prognostic tool applicable
to routine clinical practice. We explored whether tumoral tissue
transcriptional profiling might unveil signatures indicative of
response to preoperative CRT.
Material and Methods
Study cohort
The study was approved by the Ethics Committee (CEI
Granada), Department of Health, Government of Andalucı́a,
Spain. Participants provided written consent in accordance with
institutional and national guidelines; consent procedure was also
approved by the Ethics Committee.
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The microarrays study included a total of 35 consecutive
enrolled patients with LARC treated at our Division of Colon &
Rectal Surgery of the Virgen de las Nieves University Hospital
with additional 8 patients in the validation group.
The inclusion criteria were: histologically proven rectal tumor at
a clinical stage II-III (cT3-4/and or N positive) following
endorectal ultrasound and/or MRI scan. Patients were excluded
if they had tumor located above 13 cm from the anal verge by
rigid rectoscopy, colonic cancer assessed by colonoscopy, distant
metastases by abdominal and thoracic PET-CT scan, and
suspicion of hereditary colorectal cancer.
Pretherapeutic staging was performed, including complete
medical history and physical evaluation, digital rectal examination,
endorectal ultrasound, rigid rectoscopy, colonoscopy, PET-TC
and MRI. Tumor samples were prospectively obtained upon
rectoscopy. All patients included subsequently received a total dose
of 50.4Gy of radiation (28 fractions of 1.8Gy) associated with
capecitabine alone or capecitabine combined with oxaliplatine,
according to our Hospital Clinical Practice Guidelines. Standard-
ized surgery was performed, including total mesorectal excision,
after an interval of 8 weeks after CRT.
The tumor response was assessed in surgical specimens by
pathological examination based on the semiquantitative tumor
regression grading (TRG) system described by Mandard in 1994
[5]: TRG1 and TRG2 scores were considered responders,
whereas TRG3, TRG4, and TRG5 scores were classified as
non-responders.
RNA isolation and microarray analyses
Frozen sample materials were provided by the Tissue and
Tumor Bank, Department of Pathology at the Virgen de las
Nieves Hospital. RNA was extracted from macrodissected frozen
samples according to standard procedures using RNesasy minikit
(Qiagen Sciences). RNA quantity and integrity were checked by
spectrophotometry in a NanoDrop (ND-1000, DE, USA) and in
an Experion automated electrophoresis system (Bio-Rad, Rich-
mond, VI, USA), respectively. Prior to extraction, 8 mm sections
were stained with hematoxylin and eosin for microscopic
examination to check the percentage of tumor cells. The
percentage of tumor cells was estimated by an experienced
pathologist in each case via visual inspection.
Microarrays were done in duplicate using 10 mg of cRNA. After
reverse transcription, cRNAs were labeled with Cy5 streptavidine.
Hybridization of 20,000 human genes CodeLink bioarrays
(Applied Microarrays, Tempe, Ariz, USA) was performed
overnight at 37uC in a shaker. Microarrays were read with a
GenePix 4000B laser scanner (Axon Instruments, CA), quantified,
and normalized with CodeLink Software 4.2 (Applied Micro-
arrays, Tempe, AZ).
Microarray data were normalized using different normalization
methods: average normalization and cyclic loess [6]. The quality
of the outcome was assessed by different plots produced by the
software package ArrayQualityMetrics implemented in the R
language. Samples were grouped Responders and Non-Respond-
ers, and the differential expression of genes was then evaluated
using the software SAM (Significance Analysis of Microarrays,
Stanford University, Stanford, CA). Genes with p-values ,0.05
were considered as significantly differentially expressed between
the two subgroups. This set of genes constitutes our molecular
signature to predict response to treatment after CRT.
Raw and normalized gene expression values for each sample
under study have been made publicly available at the Gene
Expression Omnibus GEO database with submission number
GSE53781.
Functional analysis of gene expression results
To obtain information about the biological signature and to
analyze the biological coherence of the microarray results, gene
expression data were analyzed using Ingenuity Pathways Analysis
(IPA) v.5.0 (Ingenuity Systems Inc, Redwood City, CA). This tool
provides information about diseases, molecular function and
biological process categories, as well as biological pathways related
to the genes obtained from the microarray analysis. Ingenuity
Pathways Analysis was also used to identify potential biomarkers.
In addition, IPA maps each gene within a global molecular
network developed from information contained in the Ingenuity
Pathways Knowledge Base. Gene networks are generated algo-
rithmically based on their connectivity in terms of expression,
activation, transcription, and/or inhibition. A network in IPA is
defined as a graphical representation of the molecular relation-
ships between genes, represented with nodes, and the biological
relationship between them represented by connecting lines. All
connections are supported by published data stored in the
Ingenuity Pathways Knowledge Base and/or PubMed. IPA ranks
all genes based on their connectivity, using a generalization of the
concept of node degree, which measures the number of single
genes to which a gene is connected.
Quantitative Reverse Transcription-PCR analysis
(qRT-PCR)
To validate microarray experimental data, we determined the
level of expression of 20 genes in rectal tumor patients by real-time
quantitative reverse transcription-PCR. In addition, to validate
selected candidate genes, an independent series of 8 consecutive
LARC was analyzed using qRT-PCR.
The genes Abcb7, Cd81, Chmp4b, Cri2, Ect2, Ska2, Gng4,
Id1, Mmp12, c-Myc, Nat5, Rrm1, Rfsbp1, Stmn1, Stmn2,
Top1mt, Mapk9, P53csv, Dpm1, and Pola1, were selected for
this validation among the obtained set of genes that discriminates
Responders vs. Non-Responders. In addition, the tumor protein
53 (Tp53) and the cyclin-dependent kinase inhibitor 1a (Cdkn1a)
were also analyzed due to their relation to colorectal cancer. We
optimized a sensitive and specific qRT-PCR assay using
MX3005P QPCR System (Agilent Technologies, Santa Clara,
CA). One microgram of RNA was used for reverse transcription
with QPCR-grade AffinityScript Multiple Temperature Reverse
Transcriptase (AffinityScript QPCR cDNA, Agilent Stratagene)
using random hexamers. PCR reactions contained 1 mg cDNA,
12.5 mL qPCR Master Mix, 12.5 uL of solaris qPCR master mix,
1.25 uL of solaris primer/probe set for each gene. PCR conditions
were 15 min at 95uC, 15 s at 95uC and 1 min at 60uC for 40
cycles. We designed specific Taqman probes and primers for each
gene (Table S1). The cycle threshold (Ct, the PCR cycle at which
probe signal reaches the threshold) was determined for each gene.
Before performing this study, Gapdh, Rpl13a, and Tbp were
selected as candidate housekeeping genes. Gapdh emerged as the
most stable gene with no closely comparable housekeeping gene
among the evaluated genes in the series of tumors. Expression was
quantified following the analysis of two different dilutions of
cDNAs (1 and 1/10) in triplicate. For each experimental sample,
the amount of each gene and endogenous reference (Gapdh) was
determined from the standard curves. These standard curves were
composed of five points obtained from five-fold serial dilutions (1,
1/10, 1/50, 1/100, and 1/500) of cDNA from Universal Human
Reference RNA (Stratagene). This cDNA is composed of total
RNA from 10 human cell lines. We considered only experiments
in which the linear relationship between Ct (threshold cycle) and
the log of the amount of standard curve for each gen and, Gapdh
were higher than 0.99 (correlation coefficient). The average Ct of
Response to Treatment Signature in Rectal Cancer
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the triplicates was calculated, excluding outliers (replicates with Ct
differing by more than one cycle from the median). If the sample
failed to meet these criteria a third time, it was classified as an
assay failure. The expression values of each gene were then
divided by the amount of Gapdh to obtain a normalized value.
Gapdh gene was used as an internal control for RNA quality
reverse transcription and to correct the variations in the degree of
RNA degradation.
Fluorescence in situ hybridization (FISH)
Paraffin-embedded pre-treatment core biopsies from patients
with LARC (7 Responders and 6 Non Responders) were tested for
c-Myc amplification. For the detection of c-Myc amplification we
used the c-Myc dual fusion break-apart (Dako, Santa Clara, CA;
Y5410) and CEP 8 (Dako 30-170008) probes, and followed the
manufacturer’s recommendations.
The c-Myc dual-fusion probe consists of pairs of probes labeled
in distinct colors (red and green), with each probe binding to a
different part of the gene. The FISH DNA probes are a mixture of
a Texas Red-labeled DNA probe (c-Myc-downstream) covering
418 kb telomeric to the c-Myc breakpoint cluster region and a
fluorescein-labeled DNA probe (c-Myc-upstream) covering 652 kb
centromeric to the c-Myc breakpoint cluster region. In a normal
intact cell, two separate red and two separate green individual
signals will be visible, whereas an altered pattern of c-Myc would
generate two fused red/green signals (often appearing as single
yellow signals), accompanied by one red and one green signal
(representing the normal loci). To identify and enumerate
chromosome 8, we used the centromere 8 (CEP8) DNA probe
that detects rich alpha satellite sequences in the centromere region
of chromosome 8.
The FISH testing methodology is a semiquantitative method
based on the computation of the average ratio of c-Myc signals to
CEP8 signals in non-overlapping interphase nuclei of the lesion.
Tumors with a c-Myc: CEP8 ratio . = 2:1 were considered
positive for gene amplification. The c-Myc and CEP8 signals were
visualized by two blinded and independent pathologists.
All cases without a consensus diagnosis were reviewed jointly on
a multiheaded microscope and discussed by the two blinded expert
pathologists.
Immunohistochemical analysis
Immunohistochemistry with antibody against c-Myc was
performed. 4 mm thick in formalin-fixed paraffin-embedded tissue
(FFPE) full tissue sections were stained for c-MYC (rabbit
monoclonal anti-human c-MYC antibody; catalog #1472-1,
Epitomics, Inc., Burlingame, CA) in the Specialized Histopathol-
ogy Laboratory and the Anatomic Pathology Immunohistochem-
istry Laboratory (Spanish National Cancer Centre) on Ventana
Benchmark XTs (Ventana Medical Systems, Tucson, AZ) using
extended antigen retrieval (CC1 buffer), anti-c-MYC antibody
(final concentration 0.56 mg/mL) and signal amplification (mouse
anti-rabbit reagent followed by rabbit anti-mouse reagent).
The percentage of positive tumor nuclei was manually scored
from 0 to 100% in 10% intervals. Independent scoring by two
blinded expert pathologists showed concordance for final c-Myc
score.
Statistical analysis
To determine differences in clinicopathological features be-
tween response and non-response patients, Student t-test was used
to compare means of continuous variables, and Chi-square or 2-
sided Fisher exact test were chosen for categorical variables.
Statistical significance of differences in transcript levels was
assessed using the non-parametric T-test (Mann Whitney).
Data analyses were carried out with the SPSS statistical
software, version 15.0 (SPSS Inc., Chicago, IL). Sample size was
calculated to obtain a power of 0.8.
Results
Patient and tumor characteristic
Nine of the initial 35 patients were excluded due to the poor
quality of the RNA or contradictory results of Mandard’s criteria
and histopathological downstaging. Complete clinical data re-
garding, age, sex, stage of disease, response to therapy, and overall
survival from 26 patients (10 responders and 16 non-responders) is
shown in Table 1. The patient cohort was homogeneous, no
statistically significant differences were found in terms of CRT,
surgery or sex when comparing the two groups (response vs. non-
response) (Table 2). The main characteristics of the 8 patients
included in the validation set are shown in Table 1.
Differential gene expression between treatment
responder and non responder rectal tumor patients
A supervised method (Significance Analysis of Microarrays
-SAM-) was used to find statistically significant (adjusted p,0.05)
differentially expressed genes between treatment responder and
non-responder LARC patients. We found 260 clones, representing
257 genes (Table S2), that were differentially expressed between
these two subgroups. All of them presented significantly higher
expression levels in responder LARC samples. A hierarchical
clustering analysis was then performed on both the genes and the
samples based on the expression values of these 257 genes in the
26 rectal tumoral samples (Figure S1). Samples were clustered
into 2 main subgroups (branches). One of the subgroups contained
half of the responder tumor samples, and they clearly showed
over-expression of these genes, while the other subgroup was
characterized by lower expression of them. The other branch of
samples contained the remaining responder samples, and non
responder samples. This subgroup also contained four branches; in
one of them 40% of responder tumor patients were grouped
together. Differences in expression of the genes between responder
and non responder rectal tumor samples cannot be explained by a
different content of tumor cells within the samples since the
estimation of tumor cells in the tumor samples showed no
significant differences between these two subgroups (data not
shown).
In order to better understand the biological meaning of the
genes showing higher expression levels in responder rectal tumor
patients, data from these 257 genes were analysed using the IPA
software to enable the identification of interacting genes within our
networks that were not part of our focus gene lists. An analysis of
the identified genes (p,0.05) showed that the encoding proteins
associated with several canonical pathways, such as Pyrimidine
and Purine Metabolism (p = 0.022), and Colorectal Cancer
Metastasis Signalling (p = 0.02). In the diseases and disorders,
and molecular and cellular function categories, most of these genes
were related to Cancer (p,0.001), and Cellular Growth and
Proliferation (p,0.001), involving 33 and 19 molecules respec-
tively. IPA software was also used to build up networks that
involved the selected 257 genes. The most significant IPA network
consisting of 49 genes, contained 24 focus genes (Nkrd32, Cnp,
Dars, Ddx28, Ect2, Gmnn, Gtf2f2, Id1, Mapk9, Mcm3, Mrpl12,
Myc, Ndufb5, Oip5, Pola1, Ppap2c, Racgap1, Rad18, Ska2,
Smc1a, Stmn1, Stmn2, Tom1l1, and Ube3a) with direct or
indirect connections related to gene expression, protein-DNA and
Response to Treatment Signature in Rectal Cancer
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protein-protein interactions. These genes were directly or
indirectly connected to a c-Myc network. The c-Myc network,
in which red-labelled symbols indicate 24 genes contained in our
list of 257 genes, is shown in Figure 1.
Real-Time Reverse Transcriptase (RT)-PCR Validation of
Microarray Observations
To confirm the findings obtained in the expression array, qRT-
PCR was performed for selected genes in 24 LARC samples:
responder (n = 10) and non responder (n = 14). Samples of 2
patients (6 and 9) were not analyzed because of poor RNA quality.
Among the genes of the c-Myc apoptosis pathway, c-Myc, Mapk9
(one of the main kinases involved in the phosphorylation of c-
Myc), and the Id1 and Stmn1 genes, downstream targets of c-Myc,
were selected to analyze their expression by real-time RT-PCR. In
addition, we analysed other genes related to c-Myc apoptosis and
proliferation (Tp53, P53csv, Pola1, Cdkn1a, Top1mt, Rrm1, and
Ska2), as well as genes involved in angiogenesis (Mmp12), and
transport (Abcb7, and Chmp4b). Highly concordant results were
obtained for all these genes with statistically significant differences
between these two groups of LARC patients (Figure S2).
Validation of predictive biomarkers
For the genes Gng4, c-Myc, Pola1 and Rrm1 (a subset of the
gene signature obtained by the microarray analyses) we computed
receiver operating characteristic (ROC) curves. Area under curve
(AUC) values and 95% confidence intervals (CI) were calculated to
determine the specificity and sensitivity of response to treatment
prediction. ROC curves of Gng4, c-Myc, Pola1 and Rrm1
microarray data reflected the ability to distinguish between the
responder subgroup and non-responder subgroup, with an AUC
of 0.750, 0.862, 0.850 and 0.806, respectively. For Gng4 the cut-
off point set at 5.59 yielded a sensitivity of 70% and a specificity of
81.3%. At a cut-off point set at 64.45 for c-Myc yielded a
sensitivity of 70% and a specificity of 100%. At a cut-off point set
for Pola1 at 167.64 yielded a sensitivity of 60% and a specificity of
87.5%. At a cut-off point set at 5.52 for Rrm1 yielded a sensitivity
of 60% and a specificity of 75%. For best result, the ROC curve
was generated with data from c-Myc qRT-PCR. Sensitivity (60%)
and specificity (80%) were worse with an AUC value of 0.733 (all
data available in Table S3).
We then assessed the power of the selected genetic signature
(Gng4, c-Myc, Pola1 and Rrm1) to predict response to therapy in
LARC. We considered a test positive when at least 3 of the 4 genes
were over-expressed in the sample under study. The genetic
signature achieved 60% sensitivity, 100% specificity, and 85%
accuracy to identify responder patients.
Gen amplification (rewrite headline)
Fluorescence in situ hybridization (FISH) was applied to LARC
for the detection of c-Myc amplification, and the results were
compared with expression levels of c-Myc mRNA. Successful
probe hybridization was achieved in 13 cases (7 responders and 6
non-responders). Representative results of FISH examination of c-
Myc are shown in Figure 2. We found an altered pattern of c-
Myc in 5 of 13 tumors (38%): 4 Responder and 1 Non-Responder
LARC samples; however, they also had two number of centromere
8 signals. Amplification of c-Myc was not seen in any studied cased
with LARC, suggesting that overexpression of c-Myc can also
occur via mechanisms independent of gene amplification.
c-Myc detection for immunohistochemistry
Immunohistochemical analysis was also performed for c-Myc to
study whether the differences in the expression detected by
microarray analysis could also be detected at a protein level.
IHC analysis of 12 pre-treatment LARC (6 Responder and 6
Non-Responder) cases revealed a spectrum of total tumor cell
nuclei (ranging from 90% to100%) that stained positive for c-Myc
by manual scoring. Responder tumors exhibited strong c-Myc
staining intensity. Non tumoral cells within the tumor did not
express c-Myc protein.
The study of c-Myc activation based on the expression of c-Myc
protein did not reveal differences in the intensity of this protein in
the different patient subgroups (responder versus non-responder),
suggesting that post-translational modifications, as well as the half-
live or abundance might affect the relationships between the two
data types.
Discussion
Gene expression profiling using microarray technology has led
to a series of promising results though tissue gene expression
profiling of different malignancies, including cancer. Nevertheless,
to date, none of the identified signatures or molecular markers in
LARC has been successfully validated as a diagnostic or prognostic
tool applicable to routine clinical practice. Moreover, there has
been little agreement between signatures, with scarce overlap in
the reported genes [4]–[16]. Only two genes, MMP4 and FLNA,
have been reported in more than one paper [7], [8], [13] and one
Table 2. Patient characteristic stratified by response to treatment.
Responders Non responders p
Sex 0.668
Woman 2 (20%) 5 (31.3%)
Man 8 (80%) 11 (68.7%)
Age (mean values 6 standard deviation) 63.263.5 59.563.2 0.473
Chemotherapy 0.689
Capecitabine 5 (50%) 10 (62.5%)
Capecitabine + oxaliplatine 5 (50%) 6 (37.5%)
Surgical technique 1.000
Low anterior resection 9 (90%) 13 (81.2%)
Abdmino-perineal resection 1 (10%) 3 (18.8%)
doi:10.1371/journal.pone.0112189.t002
Response to Treatment Signature in Rectal Cancer
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of the 257 genes reported in this study RRM1 (an important
marker for chemotherapy resistance in colon tumors [17]), was
also identified by Nishioka [13]. This could be due to variations in
the inclusions criteria, schedule of neoadjuvancy, sample collec-
tion, patient characteristics, definition of response, types of
platform used and data analysis. Furthermore, recent investiga-
tions suggest the importance not only of the tumor tissue itself but
also of the immune system’s dysregulation assessed in the
peripheral blood of patients with LARC [18]. The lack of large-
scale studies and the difficulty to understand and select which data
would be informative and useful for a reliable clinical application
offer further discussion and variability among the studies [19].
However, considering the utility of gene expression profiling in
other tumors, like breast cancer, expression profiling of LARC
could be crucial to improve the management of these patients.
The results reported here show the expression patterns of
response to CRT in LARC patients. Many of the genes were
related to the Cellular Growth and Proliferation IPA category, and
were over-expressed in patients who responded to treatment. They
included a broad range of genes involved in cell-cycle control,
DNA synthesis, and c-Myc network such as Gng4, Mapk9, Mcm3,
c-Myc, Pola1, Polr2k, and Rrm1, suggesting that LARC cells in
CTR-(?) responders present a higher proliferative rate compared
to non-responders. Although this hypothesis will need to be
confirmed by direct analysis of cell cycle in LARC tumor samples,
our results are in agreement with previous studies showing an
increased proliferative capacity of tumor cells in patients that
respond to treatment [20]. We demonstrated that high Gng4, c-
Myc, Pola1, and Rrm1 mRNA expression levels were a significant
prognostic factor for response to treatment in LARC patients (p,
0.05). Using this gene set, we were able to establish a new model to
Figure 1. IPA’s Key regulatory network over-expressed in responder patients. A network is a graphical representation of the relationships
between molecules. Molecules are represented as nodes, and the biological relationship between 2 Ingenuity nodes is represented as an edge (line).
All edges are supported by at least 1 reference from the literature, from a textbook, or from canonical information stored in the Ingenuity Knowledge
Base. Network analysis analyses identified two major inducers: c-Myc and Pola1.
doi:10.1371/journal.pone.0112189.g001
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predict response to radiotherapy in rectal cancer with a sensitivity
of 60% and a high specificity of 100%. These findings indicate that
up-regulation of these genes could represent an independent
predictor of response to treatment in LARC patients. It is
necessary to further identify the specific mechanisms involved in
this process to further understand the response to treatment of
LARC.
Understanding of the function of c-Myc could increase our
understanding of the biology of the responder LARC patients but
also may provide a novel therapeutic molecular target for clinical
practice. However, the prognostic value for the over-expression of
c-Myc mRNA has not been analyzed in rectal tumors, and it
should be noted that our cohort of patients is small, and that these
results will need to be validated in additional patient cohorts and
across multiple institutions.
Deregulation and over-expression of c-Myc, in addition to
having proliferative effects, is frequently associated with an
apoptosis-prone phenotype [21]. Thus opening the possibility of
therapeutic intervention due to rapidly proliferating cells are
generally more sensitive to chemotherapy. However, the relation-
ship between c-Myc expression and its apoptosis-promoting effects
of more clinically relevant chemotherapeutic agents on rectal
cancer cells has not been investigated. This could be important
since amplification of c-Myc was identified in primary colon tumor
patients with increased disease-free (tumor clearance?) and overall
survival after 5-fluorouracil (5-FU) based adjuvant therapy, and
amplification of c-Myc was shown to result in a further up-
regulation of c-Myc ‘‘in vitro’’ [22]. In contrast, c-Myc expression
was associated with reduced cancer specific survival in rectal
cancer patients [23]. We suggest that up-regulation of c-Myc in
rectal cancer cells results in a markedly increased sensitivity to
apoptosis induced by fluoropyrimidine capecitabine which is
enzymatically converted to 5-FU in the tumor, where it inhibits
DNA synthesis and slows growth of tumor tissue. Since 5-FU is an
S-phase specific drug, and only active during certain cell cycles,
those LARC patients, showed higher expression levels of Cellular
Growth and Proliferation signature, and c-Myc, could respond
better to the treatment
Physiologically, c-Myc DNA, mRNA and protein levels are
tightly regulated. The high levels of Myc mRNA in LARC could
be attributed to gain of c-Myc DNA or aberrant transcriptional
activation. However, when we examined rectal tumors before
CRT, we found no evidence of gene amplification, according to
(which is in agreement with) previous colorectal studies [24]. While
higher c-Myc mRNA expression levels correlated with response to
treatment, a non significant correlation was found in our study
between c-Myc mRNA overexpression in the tumor and c-Myc
gene amplification, suggesting that overexpression of c-Myc also
can occur via mechanisms independent of gene amplification [25],
such as chromosomal translocations [26], point mutations in the
coding sequence of the promoter region [27]–[30], or activation/
deactivation of trans-activating factors. Finally, we studied the
relationship between c-Myc mRNA and protein expression levels.
Previous studies have recognized the diagnostic significance of
immunohistochemical analysis for c-Myc in human rectal cancers
[31] although the limited amounts of pre-treatment biopsy
material impede the analysis of c-Myc at the protein level. In
interpreting our gene expression data, we generally assume that
protein levels in these tissue samples reflect the expression of their
corresponding mRNAs. However, both responder and non-
Figure 2. Representative fluorescence in situ hybridization (FISH) signal patterns using the c-Myc break-apart and CEP8 probe in
locally advanced rectal cancer (LARC); a, b) c-Myc rearrangement is absent as evidenced by the presence of normal red-green
fusion signals only. Multiple copies (3–4 copies or 4–6 copies) of c-Myc are present in the tumor; c, d) Two copies of chromosome 8.
doi:10.1371/journal.pone.0112189.g002
Response to Treatment Signature in Rectal Cancer
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responder tumor patients overexpressed c-Myc protein indepen-
dently of their c-Myc RNA expression levels. Biological reasons for
this poor correlation between c-Myc mRNA and protein levels
could include post-translational modifications, as well as the
protein’s half-live [32]. We acknowledge that this needs not to be
the case, as post-transcriptional, translational and protein degra-
dation controls probably have a significant influence in LARC.
Novel observations from this study were the distinct expression of
c-Myc in adenocarcinoma and its adjacent normal tissue samples,
and the range of c-Myc protein expression in LARC.
Conclusion
We demonstrated that high Gng4, c-Myc, Pola1, and Rrm1
mRNA expression levels was a significant prognostic factor for
response to treatment in LARC patients. Using this gene set, we
were able to establish a new model to predict response to
radiotherapy in rectal cancer with a sensitivity of 60% and a high
specificity of 100%. Moreover, the information obtained from this
study supports the hypothesis that elevated expression of c-Myc
mRNA is an important marker of response to CRT in LARC as
an essential component of the neoplastic phenotype in rectal
tumors.
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Sánchez-Sánchez R, et al. (2010) The value of metabolic imaging to predict
tumour response after chemoradiation in locally advanced rectal cancer. Radiat
Oncol 5: 119.
3. Horisberger K, Hofheinz RD, Palma P, Volkert AK, Rothenhoefer S, et al.
(2008) Tumor response to neoadjuvant chemoradiation in rectal cancer:
Predictor for surgical morbidity? Int J Colorectal Dis 23: 257–264.
4. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, et al.
(1994) Pathologic assessment of tumor regression after preoperative chemor-
adiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer
73: 2680–2686.
5. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of
normalization methods for high density oligonucleotide array data based on bias
and variance. Bioinformatics 19, 185–193.
6. Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, et al. (2005)
Effectiveness of gene expression profiling for response prediction of rectal
adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23: 1826–
1838.
7. Watanabe T, Komuro Y, Kiyomatsu T, Kanazawa T, Kazama Y, et al. (2006)
Prediction of sensitivity for rectal cancer cells in response to preoperative
radiotherapy by DNA microarrays analysis of gene expression profiles. Cancer
Res 66: 3370–3374.
8. Kim IJ, Lim SB, Kang HC, Chang HJ, Ahn SA, et al. (2007) Microarray gene
expression profiling for prediciting complete response to preoperative chemor-
adiotherapy in patients with advanced rectal cancer. Dis Colon Rectum 50:
1342–1353.
9. Ojima E, Inoue Y, Miki C, Mori M, Kusunoki M (2007) Effectiveness of gene
expression profiling for response prediction of rectal cancer to preoperative
radiotherapy. J Gastroenterol 42: 730–736.
10. Rimkus C, Friederichs J, Boulesteix AL, Theisen J, Mages J, et al. (2008)
Microarray-based prediction of tumor response to neoadjuvant radiochemother-
apy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol
6: 53–61.
11. Snipstad K, Fenton CG, Kjaeve J, Cui G, Anderssen E, et al. (2010) New
specific molecular targets for radio-chemotherapy of rectal cancer. Mol Oncol 4:
52–64.
12. Brettingham-Moore KH, Duong CP, Greenawalt DM, Heriot AG, Ellul J, et al.
(2011) Pretreatment transcriptional profiling for predicting response to
neoadjuvant chemoradiotherapy in rectal adenocarcinoma. Clin Cancer Res
17: 3039–3047.
13. Nishioka M, Shimada M, Kurita N, Iwata T, Morimoto S, et al. (2011) Gene
expression profile can predict pathological response to preoperative chemor-
adiotherapy in rectal cancer. Cancer Genomics Proteomics 8: 87–92.
14. Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S,
et al. (2012) A specific miRNA signature correlates with complete pathological
response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Int J Radiat Oncol Biol Phys 83: 1113–1119.
15. Saigusa S, Tanaka K, Toiyama Y, Matsushita K, Kawamura M, et al. (2012)
Gene expression profiles of tumor regression grade in locally advanced rectal
cancer after neoadjuvant chemoradiotherapy. Oncol Rep 28: 855–861.
16. Gantt G, Chen Y, Dejulius K, Mace A, Barnholtz-Sloan J, et al. (2013) Gene
expression profile is associated with chemoradiaton resistance in rectal cancer.
Colorectal Dis 16: 57–66.
17. van de Wiel MA, Costa JL, Smid K, Oudejans CB, Bergman AM, et al. (2005)
Expression microarray analysis and oligo array comparative genomic hybrid-
Response to Treatment Signature in Rectal Cancer
PLOS ONE | www.plosone.org 8 November 2014 | Volume 9 | Issue 11 | e112189
ization of acquired gemcitabine resistance in mouse colon reveals selection for
chromosomal aberrations. Cancer Res 65: 10208–10213.
18. Palma P, Cuadros M, Conde-Muı́ño R, Olmedo C, Cano C, et al. (2013)
Microarray profiling of mononuclear peripheral blood cells identifies novel
candidate genes related to chemoradiation response in rectal cancer. PLoS One
8: e74034.
19. Akiyoshi T, Kobunai T, Watanabe T (2012) Predicting the response to
preoperative radiation or chemoradiation by a microarray analysis of the gene
expression profiles in rectal cancer. Surg Today 42: 713–719.
20. Sasaki K, Tsuno NH, Sunami E, Kawai K, Hongo K, et al. (2012) Resistance of
colon cancer to 5-fluorouracil may be overcome by combination with
chloroquine, an in vivo study. Anticancer Drugs 23: 675–682.
21. Prendergast GC (1999) Mechanisms of apoptosis by c-Myc. Oncogene 18:
2967–2987.
22. Arango D, Corner GA, Wadler S, Catalano PJ, Augenlicht LH (2001) c-myc/
p53 interaction determines sensitivity of human colon carcinoma cells to 5-
fluorouracil in vitro and in vivo. Cancer Res 61: 4910–4915.
23. Aamodt R, Jonsdottir K, Andersen SN, Bondi J, Bukholm G, et al. (2009)
Differences in protein expression and gene amplification of cyclins between
colon and rectal adenocarcinomas. Gastroenterol Res Pract 2009: 285830.
24. Smith DR, Myint T, Goh HS (1993) Over-expression of the c-Myc proto-
oncogene in colorectal carcinoma. Br J Cancer 68: 407–413.
25. Dang CV (1999) c-Myc Target Genes Involved in Cell Growth, Apoptosis, and
Metabolism Mol Cell Biol19: 1–11.
26. Potter M, Wiener F (1992) Plasmacytomagenesis in mice: model of neoplastic
development dependent upon chromosomal translocations. Carcinogenesis 13:
1681–1697.
27. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, et al. (1993) Point
mutations in the c-Myc transactivation domain are common in Burkitt’s
lymphoma and mouse plasmacytomas. Nat Genet 5: 56–61.
28. Bhatia K, Spangler G, Gaidano G, Hamdy N, Dalla-Favera R, et al. (1994)
Mutations in the coding region of c-myc occur frequently in acquired
immunodeficiency syndrome-associated lymphomas. Blood 84: 883–888.
29. Clark HM, Yano T, Otsuki T, Jaffe ES, Shibata D, et al. (1994) Mutations in the
coding region of c-MYC in AIDS-associated and other aggressive lymphomas.
Cancer Res 54: 3383–3386.
30. Yano T, Sander CA, Clark HM, Dolezal MV, Jaffe ES, et al. (1993) Clustered
mutations in the second exon of the MYC gene in sporadic Burkitt’s lymphoma.
Oncogene 8: 2741–2748.
31. Lin MS, Chen WC, Huang JX, Gao HJ, Zhang BF, et al. (2011) Tissue
microarrays in Chinese human rectal cancer: study of expression of the tumor-
associated genes. Hepatogastroenterology 58: 1937–1942.32.
32. Pascal LE, True LD, Campbell DS, Deutsch EW, Risk M, et al. (2008)
Correlation of mRNA and protein levels: cell type-specific gene expression of
cluster designation antigens in the prostate. BMC Genomics 23: 246.
Response to Treatment Signature in Rectal Cancer
PLOS ONE | www.plosone.org 9 November 2014 | Volume 9 | Issue 11 | e112189
